Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
DERMATA THERAPEUTICS INC (DRMA) Stock Price & Overview
NASDAQ:DRMA • US2498455045
Current stock price
1.33 USD
-0.04 (-2.92%)
At close:
1.3 USD
-0.03 (-2.26%)
After Hours:
The current stock price of DRMA is 1.33 USD. Today DRMA is down by -2.92%. In the past month the price increased by 3.1%. In the past year, price decreased by -84.71%.
DRMA Key Statistics
52-Week Range1.1 - 9.899
Current DRMA stock price positioned within its 52-week range.
1-Month Range1.19 - 1.41
Current DRMA stock price positioned within its 1-month range.
- Market Cap
- 5.347M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -9.33
- Dividend Yield
- N/A
DRMA Stock Performance
Today
-2.92%
1 Week
+7.26%
1 Month
+3.10%
3 Months
-40.89%
Longer-term
6 Months -61.11%
1 Year -84.71%
2 Years -96.53%
3 Years -99.45%
5 Years N/A
10 Years N/A
DRMA Stock Chart
DRMA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to DRMA. When comparing the yearly performance of all stocks, DRMA is a bad performer in the overall market: 97.42% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
DRMA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DRMA. DRMA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
DRMA Earnings
Next Earnings DateMay 12, 2026
Last Earnings DateMar 26, 2026
PeriodQ4 / 2025
EPS Reported-$1.52
Revenue Reported
EPS Surprise 3.23%
Revenue Surprise %
DRMA Forecast & Estimates
7 analysts have analysed DRMA and the average price target is 4.08 USD. This implies a price increase of 206.77% is expected in the next year compared to the current price of 1.33.
Analysts
Analysts82.86
Price Target4.08 (206.77%)
EPS Next Y75.95%
Revenue Next YearN/A
DRMA Financial Highlights
Over the last trailing twelve months DRMA reported a non-GAAP Earnings per Share(EPS) of -9.33. The EPS increased by 93.91% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-7.56M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -96.12% | ||
| ROE | -121.45% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%92.62%
Sales Q2Q%N/A
EPS 1Y (TTM)93.91%
Revenue 1Y (TTM)N/A
DRMA Ownership
Ownership
Inst Owners3.16%
Shares4.02M
Float2.94M
Ins Owners20.7%
Short Float %6.81%
Short Ratio0.11
DRMA Industry Overview
DRMA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
DRMA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DRMA
Company Profile
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Company Info
IPO: 2021-08-13
DERMATA THERAPEUTICS INC
3525 Del Mar Heights Rd., #322
San Diego CALIFORNIA US
CEO: Gerald T. Proehl
Employees: 9
Phone: 18582230882
DERMATA THERAPEUTICS INC / DRMA FAQ
What does DERMATA THERAPEUTICS INC do?
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Can you provide the latest stock price for DERMATA THERAPEUTICS INC?
The current stock price of DRMA is 1.33 USD. The price decreased by -2.92% in the last trading session.
Does DRMA stock pay dividends?
DRMA does not pay a dividend.
What is the ChartMill rating of DERMATA THERAPEUTICS INC stock?
DRMA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is DERMATA THERAPEUTICS INC (DRMA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DRMA.
Can you provide the short interest for DRMA stock?
The outstanding short interest for DERMATA THERAPEUTICS INC (DRMA) is 6.81% of its float.